...
首页> 外文期刊>Clinical cancer research: an official journal of the American Association for Cancer Research >The prognostic significance of vasohibin-1 expression in patients with upper urinary tract urothelial carcinoma
【24h】

The prognostic significance of vasohibin-1 expression in patients with upper urinary tract urothelial carcinoma

机译:血管抑制素-1表达在上尿路尿路上皮癌患者中的预后意义

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Purpose: Vasohibin-1 (VASH1) is a novel angiogenic molecule that is specifically expressed in activated vascular endothelial cells, and the status of VASH1 expression has been documented in cancer angiogenesis. The aim of this study was to address the prognostic value of VASH1 expression in upper urinary tract urothelial carcinomas (UTUC). Experimental Design: We retrospectively analyzed the clinical records of 171 patients with locally advanced UTUC (Ta-3N0M0). The median follow-up period was 3.8 years. We immunohistochemically examined the accomplished microvessels with anti-CD34 as microvessel density (MVD) and the microvessels with activated endothelial cells as VASH1 density. Then, we analyzed the association between immunohistochemical expression and clinical outcomes. Results: Forty-two patients experienced tumor recurrence and of these 34 died of the disease during follow-up. VASH1 density was significantly associated with tumor grade, pathologic T stage, and MVD. The 5-year recurrence-free and cancer-specific survival rates were 66.1% and 72.8% in patients with VASH1 density (≥ 40/mm 2) and 81.0% and 86.5% in their counterparts, respectively (P 0.05). MVD was not an independent predictor of tumor recurrence or cancer-specific survival. Multivariate analyses revealed that high VASH1 density was an independent prognostic indicator of both tumor recurrence (P = 0.024, HR = 2.10) and cancer-specific survival (P = 0.031, HR = 2.23) as well as other standard prognostic factors including high tumor grade and lymphovascular invasion. Conclusions: VASH1 density represents a clinically relevant predictor of patient prognosis in UTUC. The results suggest that VASH1 density could become a new biomarker and provide additional prognostic information in patients with UTUC.
机译:目的:Vasohibin-1(VASH1)是一种新型的血管生成分子,在活化的血管内皮细胞中特异性表达,并且已在癌症血管生成中记录了VASH1表达的状态。这项研究的目的是要解决VASH1表达在上尿路尿路上皮癌(UTUC)中的预后价值。实验设计:我们回顾性分析了171例局部晚期UTUC(Ta-3N0M0)患者的临床记录。中位随访期为3.8年。我们免疫组织化学检查了完成的微血管与抗CD34作为微血管密度(MVD)和微血管与激活的内皮细胞作为VASH1密度。然后,我们分析了免疫组织化学表达与临床结果之间的关联。结果:42例患者出现了肿瘤复发,其中34例在随访期间死于该病。 VASH1密度与肿瘤分级,病理性T期和MVD显着相关。 VASH1密度(≥40 / mm 2)的患者的5年无复发生存率和癌症特异性生存率分别为66.1%和72.8%,其对应者的5年生存率分别为81.0%和86.5%(P <0.05)。 MVD不是肿瘤复发或癌症特异性生存的独立预测因子。多变量分析显示,高VASH1密度是肿瘤复发(P = 0.024,HR = 2.10)和癌症特异性生存(P = 0.031,HR = 2.23)以及其他标准预后因素(包括高肿瘤分级)的独立预后指标和淋巴管浸润。结论:VASH1密度代表UTUC患者预后的临床相关预测指标。结果表明,VASH1密度可能成为新的生物标志物,并为UTUC患者提供更多的预后信息。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号